Participant flow

Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma · Source last updated 2023-10-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   The treatment will consist of avelumab as well as a short course of Stereotactic Body Radiation Therapy

   id

   FG000

   title

   Avelumab

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      No evidence of disease

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Unevaluable

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         15

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         13

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         2

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice